Revenue: As of FY2026 Q2, the actual value is USD 29.13 M, beating the estimate of USD 26.26 M.

EPS: As of FY2026 Q2, the actual value is USD 0.07.

EBIT: As of FY2026 Q2, the actual value is USD 3.159 M.

Second Quarter 2026 Financial Results

For the second quarter ended June 30, 2026, Delcath Systems, Inc. reported total revenue of $29.1 million, an increase from $24.2 million in the second quarter of 2025. Segment Revenue: HEPZATO KIT™ revenue was $27.1 million, up from $22.5 million in the prior year. CHEMOSAT® revenue was $2.0 million, compared to $1.7 million in the second quarter of 2025. Gross Margins: Gross margins improved to 90% from 86% in the second quarter of 2025. Net Income: Net income was $2.7 million for both the second quarters of 2026 and 2025. Non-GAAP Adjusted EBITDA: Non-GAAP adjusted EBITDA for the quarter was $7.6 million, a decrease from $9.8 million in the second quarter of 2025. Operating Income: Operating income for the quarter was $2,395 thousand, down from $2,590 thousand in the second quarter of 2025. Operating Costs: Research and development expenses increased to $10.4 million from $6.9 million in the prior year, primarily due to increased clinical headcount and trial activity. Selling, general and administrative expenses rose to $13.4 million from $11.4 million, driven by continued commercial expansion activities. Cash Flow: Cash provided by operations was $5.7 million, compared to $7.3 million in the second quarter of 2025. Financial Position: As of June 30, 2026, the company held $95.9 million in cash and investments, with no debt. Other Financials: Interest income increased to $781 thousand from $649 thousand in the previous year. Other expense was - $17 thousand, compared to - $34 thousand in the second quarter of 2025. Income before income taxes was $3,159 thousand, slightly down from $3,205 thousand in the prior year. Income tax expense was $491 thousand, compared to $508 thousand in 2025. Total comprehensive income for the quarter was $2,355 thousand, a decrease from $2,908 thousand in the second quarter of 2025.

Operational Metrics

Delcath Systems, Inc. currently operates with 31 active treatment centers. The company also saw approximately 30% growth in HEPZATO volume in the second quarter of 2026 compared to the second quarter of 2025.

Outlook / Guidance

For the full fiscal year 2026, Delcath Systems, Inc. anticipates total HEPZATO KIT and CHEMOSAT revenue to range from $104 million to $108 million. This outlook reflects an expected increase in HEPZATO KIT volume of at least 28% over 2025. The company projects full-year gross margins to be in the range of 86% to 89% and expects to achieve positive adjusted EBITDA for the full year.